1. Expanding opportunities

2. Our purpose
Providing affordable and innovative medicines for healthier lives.

3. An emerging global pharmaceutical company
Established in 1984, we are a fully integrated global pharmaceutical company through three core businesses:
Pharmaceutical Services and Active Ingredients - comprising of our Active Pharmaceutical Ingredients and Custom Pharmaceutical Services business
Global Generics - which includes Branded and Unbranded generics
Proprietary Products - which includes New Chemical Entities (NCEs), Differentiated Formulations, TM Generic Biopharmaceuticals and a Dermatology focused Specialty company - Promius Pharma
Our products are marketed globally, with a strong focus on India, Russia, Europe and US. Dr. Reddy's conducts NCE research in the areas of metabolic disorders, cardiovascular diseases, anti-infectives and pain/ inflammation

4. Indian Pharma Firsts New York Stock Exchange listing
Sarbanes-Oxley (SOX) certification
180-days exclusive marketing rights for ageneric drug in the US
Authorized Generic
Commencement of Discovery Research
NCE out-licensed for development
NCE into Phase III development
Fastest to reach $1 billion in revenues
HDMA Diana Award winner (2006, 2007 and 2008)
United States Custom and Border Protection Agency certification

5. Global Pharma Firsts
USP certification under the Pharmaceutical Ingredient Verification Program
Launch of generic monoclonal antibody
Polypill (Cardiovascular) Trial

6. Driving value through collaboration
The foundation of our partnership philosophy:
Diversified business model; multiple product and service offerings
A simple, transparent and streamlined process to progress partnering discussions
Centralized Business Development Council to facilitate thorough diligence of multiple partnership opportunities and coordination between the different business units
Flat organizational structure to facilitate swift decision making
Effective alliance management processes
Adherence to highest global regulatory standards

7. The partnership process
Alliance management
Deal Execution,
Alliance Management
and Value Realization 3
Evaluation, Negotiation
and Due-Diligence 2
The partnership process
Preliminary Contact &
Opportunity Screening 1

8. Global Generics
Our Branded and Unbranded generic products offer affordable alternatives to innovator brands, both directly and through key partnerships

9. Global Generics Manufacturing Bandwidth
7 Formulation plants [6 in India (1 USFDA approved), 1 in US]
Product Portfolio
Integrated product development center
50+ products marketed in the US
130+ ANDAs filed till date. 69 ANDAs pending approval at the USFDA, of which 32 are Para IV and 19 are FTFs*
160+ products marketed in the EU
200+ branded formulations marketed in India, Russia and other emerging markets
Among the top 10 generic companies in the US; ranks 5 in Germany; the 7th largest Generic Pharma company in Russia and among the largest pharma companies in India
* As on Q3 FY09

10. Unbranded Generics
We have a significant presence in the regulated markets of USA, Germany and UK where we offer high quality medicines at affordable prices

11. Unbranded Generics Strengths • World-class distribution capabilities
• Strong product portfolio and an attractive pipeline
• Proven ability to garner market share
• Credible track record of successful “Day 1” launches
• Strong relationships with key distributors, pharmacy chains
and insurance funds
Partnering Opportunities
In-licensing, co-development and product opportunities in difficult-to-make generics
Product portfolio expansion
Partners with unique platform technologies for product development

12. Branded Generics
Our Branded Generics portfolio offers over 200 products in the major therapeutic areas of gastro-intestinal, cardiovascular, pain management, oncology, anti- infectives, paediatrics and dermatology.
Our top brands enjoy leadership positions in our key markets of India, Russia & the CIS, Romania and Venezuela

13. Branded Generics India Among the largest pharmaceutical companies
Product portfolio of over 200 brands across 13 therapeutic areas
Market leader in gastro-intestinal, cardiovascular, pain management and oncology
2000+ sales and marketing team
300,000+ doctors and stockist
Near 100% coverage of KOLs and key institutes
Stamlo, Omez, Reditux, Nise, Ketorol are market leaders in their respective category

14. Branded Generics (Contd.)
Russia
Among the top 15th pharma companies. 14th in retail segment
Fastest growing international branded generic company by volumes
Top 5 brands occupy the 1 spot in their respective molecule space
4 brands [Omez, Ketorol, Nise and Ciprolet] among Top 100
Strong presence in gastro-intestinal, cardiovascular, anti-Infective, oncology, pain and dermatology
Building capabilities in wellness and nutraceuticals
300 + sales and marketing team
Working with top 5 distributors
Coverage of 66 town classes, doctors, retailers and 500 hospitals

15. Branded Generics (Contd.)
Partnering Opportunities
In-licensing opportunities in Differentiated Products and NCEs (phase III, registered, marketed) in gastro- intestinal, cardiovascular, metabolic disorders, pain, anti-infectives and dermatology
Partnerships to build Hospital and Paediatric portfolio
Life cycle management opportunities for big brands

16. Global Oncology Strengths
One stop portfolio solution with a broad product basket for launches across the globe
Established capabilities in chemistry and biology enabling strong IP positions
Low cost development and manufacturing operations
Strong commercial infrastructure in focus Geographies
Partnering opportunities
Partners for commercialization of our portfolio
In-licensing opportunities in:
- Differentiated Products and NCEs (phase III, registered, marketed)
- Complimentary basket of oncology products
Co-development opportunities for big brands

17. Pharmaceutical Services & Active Ingredients
The Pharmaceutical Services and Active Ingredients business of Dr. Reddy's serves Generics and Innovator companies through the Active Pharmaceutical Ingredients (API) and Custom Pharmaceutical Services (CPS) businesses respectively

18. Pharmaceutical Services & Active Ingredients
Manufacturing Bandwidth
8 USFDA approved facilities (6 in India, 1 in Mexico and 1 in UK)
3 Technology Development Centers (2 in India and 1 in UK)
Among the top three API players globally
Product Portfolio
150+ APIs in the market
20 products under development at any given point of time
IP leveraged wide basket of assets
Cost effective API pipeline; end-to-end services and competitive pricing

19. Active Pharmaceutical Ingredients (API)
We offer an unparalleled portfolio to our customers, who include innovators and generic formulators worldwide. With more than 150 products, including cytotoxic and hormones, and our “first in, last out” approach, we are among the top three API players globally

20. Active Pharmaceutical Ingredients (API)
Strengths
Broad Global Portfolio: Portfolio of 140+ USDMFs, 80+ EDMFs and several filings in the Rest-of-the-World markets
Global Presence: Sales in over 85 countries
Large scale of operations: 8 USFDA approved facilities; serving 300+ SKUs across the globe; unmatched scale-up facilities
Strong product lifecycle management
Cost and technology leadership
Partnering Opportunities
Sourcing opportunities for products globally
Technology platforms to achieve breakthrough costs for better life cycle management
Partnerships to build capabilities and strengthen the overall value chain

21. Custom Pharmaceutical Services (CPS)
The CPS business today is a partner of choice for the strategic outsourcing needs of 'Innovators', both big pharma and emerging biotech companies worldwide.
Partners will benefit from our years of experience in developing and extending product life cycles and enhancing intellectual property. Our services and capabilities go beyond the boundaries of contract services and enable value creation through different stages of pharmaceutical development.

22. Custom Pharmaceutical Services (CPS)
Strengths:
Cost effectiveness, speed and flexibility in project execution
Broad service offerings
Process development and scale up to commercial manufacturing of drug substance and drug products
Customized solutions with a range of products (APIs and dosage forms)
Technology leveraged manufacturing services including chiral technology (asymmetric hydrogenation, hydroformulation and bio catalysis)
Activated mPEGs/ Pegylation
Steroidal API manufacturing
IP advantaged basket of assets
Partnering Opportunities:
Life cycle management solutions
End-to-End services in development and manufacturing

23. Proprietary Products
Our Proprietary Products business comprises of New Chemical Entities (NCEs), Generic Biopharmaceuticals, Differentiated Formulations and a Dermatology focused Specialty company - Promius Pharma.
We are building world-class capabilities and partnerships to accelerate the discovery and development of new and improved therapies in select diseases

24. Proprietary Products Development and Manufacturing Bandwidth
Discovery Research centers in India and US
cGMP E.Coli and Mammalian cell-culture manufacturing facilities with filling and finishing
Dedicated product development teams for differentiated products and Promius Pharma

25. Discovery Research Strengths
Discovery and development efforts in metabolic disorders (type 2 diabetes, obesity, dyslipidemia),anti- bacterials and pain/inflammation
History of successful R&D collaborations with external partners
Creative risk-sharing partnerships that leverage strengths in therapeutic areas of focus
Systematic project management principles and processes for timely execution and monitoring of development programs
Partnering opportunities
Co-development and commercialization partners for internal programs
In-licensing of drug delivery technology platforms in metabolic disorders, anti- bacterials and pain/inflammation

26. Biologics
We view generic biopharmaceuticals as an integral part of our mid to long term growth strategy and believe that building depth in development and manufacturing capabilities will be critical in accessing this opportunity.
We have made significant efforts in this direction and have over the years succeeded in creating world class infrastructure and a highly capable team.

27. Biologics
Strengths
Proven generic biopharmaceutical development capabilities with two marketed products - GrafeelTM (filgrastim) and RedituxTM (rituximab), in emerging markets
Developed and launched RedituxTM (rituximab) - the world's first generic monoclonal antibody
Pipeline of eight generic biopharmaceuticals in various stages of development with two in clinical development
The product portfolio spans multiple therapeutic areas - oncology, auto-immune diseases and CNS
cGMP facilities to manufacture Biologics, in adherence with global regulatory requirements at a significant cost advantage
Partnering opportunities
Partners with intent and capabilities to commercialize generic biopharmaceuticals in specific geographies
Partners developing generic biopharmaceuticals as differentiated product or for new indications and want to source product

28. Promius Pharma
Promius Pharma is a branded Specialty company with a portfolio of in-licensed dermatology products and an internal pipeline in different stages of development.
Promius Pharma's current portfolio contains innovative products for the treatment of psoriasis, atopic dermatitis and seborrheic dermatitis

29. Promius Pharma Strengths
2 products in the market: EpiCeram Skin Barrier Emulsion and Scytera Foam, 7 products in pipeline
Track record of successful partnerships with Ceragenix, Foamix, Sinclair and Antares
Strong portfolio of in-licensed and co-developed dermatological products and an internal pipeline under development
Strong and committed sales force
State-of-the-art integrated product development center in Hyderabad, India
Partnering opportunities
In-licensing and product opportunities in branded dermatology space
Interested in late stage (phase II, Phase III, ready-to-market, or in-market) opportunities for development and commercialization
Out-licensing, co-development and commercialization partners for internal programs for market outside of the US

30. Thank you